On ECHEMI
Home > Drugs > Hainan Simcere Pharmaceutical Co., Ltd.
Hainan Simcere Pharmaceutical Co., Ltd.
  • Founded in:

    1993-04-28
  • Country:

    China China
  • Address:

    No. 2, Yaogu 3rd Road, Xiuying District, Haikou City, Hainan Province
  • Tax NO.:

    91460000201357380E
  • Registered Funds:

    221.1109 million yuan
  • Website:

  • Email:

Related Drugs
Aluminum carbonate chewable tablets
Aluminum carbonate.
Name Description Content CAS NO. Registered Holders
Hydrotalcite

It has obvious anti-acid effect, and also has gastric mucosal protective effect. It also has a certain adsorption effect on bile acid. Its effect is rapid, mild and long-lasting.

More

It has obvious anti-acid effect, and also has gastric mucosal protective effect. It also has a certain adsorption effect on bile acid. Its effect is rapid, mild and long-lasting.

12304-65-3 11
Levaline besylate
Name Description Content CAS NO. Registered Holders
Levamlodipine Besylate

Unspecified

More

Unspecified

150566-71-5 0
Levoamlodipine Besylate Tablets
Levaline besylate.
Name Description Content CAS NO. Registered Holders
Levamlodipine Besylate

1. Calcium influx blocker, blocking extracellular calcium ions from entering myocardial and vascular smooth muscle cells; 2. Directly relaxes vascular smooth muscle and has anti-hypertensive effect; 3. Relieves myocardial ischemia, reduces peripheral resistance by dilating peripheral arterioles, and reduces myocardial energy consumption and oxygen demand; 4. Dilates coronary arteries and coronary arterioles to increase myocardial oxygen supply; 5. It takes a long time to metabolize in the liver, so it should be used with caution when liver function is impaired.

More

1. Calcium influx blocker, blocking extracellular calcium ions from entering myocardial and vascular smooth muscle cells; 2. Directly relaxes vascular smooth muscle and has anti-hypertensive effect; 3. Relieves myocardial ischemia, reduces peripheral resistance by dilating peripheral arterioles, and reduces myocardial energy consumption and oxygen demand; 4. Dilates coronary arteries and coronary arterioles to increase myocardial oxygen supply; 5. It takes a long time to metabolize in the liver, so it should be used with caution when liver function is impaired.

150566-71-5 0
Levofloxacin Hydrochloride Tablets
The main ingredient of this product is levofloxacin hydrochloride.
Name Description Content CAS NO. Registered Holders
Levofloxacin Hydrochloride

It achieves its antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering bacterial replication. It has good antibacterial effects on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, etc., but has poor effects on anaerobic bacteria and enterococci.

More

It achieves its antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering bacterial replication. It has good antibacterial effects on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, etc., but has poor effects on anaerobic bacteria and enterococci.

0
Roxithromycin Tablets
The main ingredient of this product is roxithromycin, and its chemical name is: 9-[0-[(2-methoxyethoxy)-methyl]oxime]erythromycin.
Name Description Content CAS NO. Registered Holders
Roxithromycin

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.

More

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.

80214-83-1 28
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.